Skip to content

The study of multi-dimensional ultrasonic intelligent quantitative evaluation of cerebral blood flow redistribution during cerebrovascular reconstruction in Moyamoya disease

The study of multi-dimensional ultrasonic intelligent quantitative evaluation of cerebral blood flow redistribution during cerebrovascular reconstruction in Moyamoya disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300067879
Enrollment
Unknown
Registered
2023-01-30
Start date
2023-02-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moyamoya disease

Interventions

Gold Standard:Functional comprehensive assessment
Index test:contrast-enhanced ultrasound, ultrafast ultrasound

Sponsors

Huashan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Normal cerebral blood perfusion: 1. Aged 18-80 years, gender unlimited; 2. Understand and sign the informed consent; 3. Non-dural tumor lesions (such as meningioma) requiring craniotomy and non-cerebrovascular disease patients were examined. Moyamoya disease: 1. Aged 18-80 years, gender unlimited; 2. Understand and sign the informed consent; 3. Patients with moyamoya disease requiring craniotomy after examination.

Exclusion criteria

Exclusion criteria: 1. Patients with severe arrhythmia; 2. Patients with respiratory failure requiring ventilator use; 3. Patients with heart disease with right-to-left shunt, patients with known severe pulmonary hypertension (pulmonary pressure > 90 mmHg), uncontrolled essential hypertension, and patients with adult respiratory distress syndrome; 4. Patients with unstable cardiovascular function whose dobutamine use is contraindicated; 5. Patients with anaphylaxis after receiving SonoVue (contrast agent) injection; 6. Patients with myocardial infarction and myocardial ischemia; 7. Patients with known pregnancies; 8. Participants in other clinical trials during the same period.

Design outcomes

Primary

MeasureTime frame
contrast-enhanced ultrasound;ultrafast ultrasound;functional comprehensive assessment;

Secondary

MeasureTime frame
CE MRI;

Countries

China

Contacts

Public ContactHong Ding

Huashan Hospital Affiliated to Fudan University

ding_hong@fudan.edu.cn+86 13651886013

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026